gpt-dict.com

D-Mannose for Urinary Symptoms (LUTS)

Verdict: Insufficient Evidence

Across 3 PubMed studies, the evidence for D-Mannose in Urinary Symptoms (LUTS) grades Tier U — unverified / insufficient. Research is still too limited to draw a firm conclusion.

U ⚫ U Unverified Insufficient Evidence

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.46
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
U · Insufficient Evidence
Confidence
81%
Highly consistent evidence
Evidence level
E5
Single large RCT (n≥500)

How strongly each layer supports this effect

lower = less supportive
L11 AI re-checkIndependent read
0.20
L2 PubMedPrimary literature
0.45
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
Against Mixed Supports
▸View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.455
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (3)L2 · primary research & systematic reviews

Cranberry, D-mannose and anti-inflammatory agents prevent lower urinary tract symptoms in women undergoing prolapse surgery
PMID: 31674202 2019 隨機對照試驗 n = 96
Finding: In postmenopausal women undergoing cystocele surgery, combination supplement improved the filling domain of LUTS questionnaire vs. control; effect not attributable to D-mannose alone (combination product, no monotherapy arm).
🟠 Limited quality Effect size: Filling-domain LUTS score improvement (p<0.05); D-mannose contribution unquantifiable
View on PubMed
D-Mannose Plus Saccharomyces boulardii to Prevent Urinary Tract Infections and Discomfort after Cystoscopy: A Single-Center Prospective Randomized Pilot Study
PMID: 37374369 2023 隨機對照試驗 n = 64
Finding: Treatment group had lower median IPSS (10.5 vs. 16.5, p=0.021) and pain score (1.5 vs. 4.0, p=0.012) 7 days post-cystoscopy; effect confounded by S. boulardii co-administration and post-procedural inflammation context (not general LUTS).
🟠 Limited quality Effect size: ΔIPSS −6 points (p=0.021)
View on PubMed
d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial (MERIT)
PMID: 38587819 2024 隨機對照試驗 n = 598
Finding: Primary endpoint (UTI episodes) not reduced: 51.0% D-mannose vs. 55.7% placebo, no significant difference. Trial explicitly excluded overactive bladder syndrome patients; LUTS frequency/urgency in absence of infection was not assessed as an outcome.
🟢 High quality Government Effect size: Risk difference −4.7% (95% CI not significant)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Advanced U-Tract consists of D-mannose, which is used to help prevent bacteria from adhering to the walls of the urinary tract and reduce the occurrence of urinary tract infections. ... Therefore, this product is intended for treatment of diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. As such, adequate directions cannot be writt… source↗
L4b EU EFSA
Against
L4c UK NHS
Cautious
D-mannose – a sugar you can buy as a powder or tablets to take every day source↗
L4d TW TFDA / 衛福部
Neutral
D-甘露糖屬自然界存在的單糖，為葡萄糖異構體，可以從植物與微生物中獲得，被廣泛應用於食品、化妝品以及醫藥業等領域。 source↗
L5e Specialty Society (condition-mapped)
Not addressed
✓PMID 100% verifiedevery citation checked via NCBI Entrez
🔬3 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-urinary-symptoms-INT-d-mannose-001 繁體中文版 →